Drug Approval | June 03, 2026
FDA fast-tracks Roche’s giredestrant review as data signal potential shift in early breast cancer care
The filing is backed by Phase III data from the lidERA Breast Cancer study
The filing is backed by Phase III data from the lidERA Breast Cancer study
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
The facility sets a new benchmark in respiratory diagnostics
The safety profile was described as manageable, though not without notable toxicities
Accreditations for Bhayla manufacturing site strengthen the company’s global quality credentials and support expansion of its hormone portfolio into regulated international markets
Acquisition provides direct access to the Dutch healthcare market, enhancing Marksans’ sales, distribution and market-access capabilities across regulated European markets
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
Real-time remote collaboration during robotic-assisted cholecystectomy showcases new possibilities for surgical mentoring, education, and knowledge sharing across institutions
Selected ventures to receive grants and structured intellectual property support to strengthen protection and management of healthcare innovations
While oncology contributed Rs. 16,100.9 million to remain company's largest therapy area, the key highlight was receipt of 11 new regulatory approvals for medicines and indications
Subscribe To Our Newsletter & Stay Updated
